Country: Canada
Language: English
Source: Health Canada
BUPIVACAINE HYDROCHLORIDE
EUGIA PHARMA INC.
N01BB01
BUPIVACAINE
2.5MG
SOLUTION
BUPIVACAINE HYDROCHLORIDE 2.5MG
BLOCK/INFILTRATION
100
Ethical
Active ingredient group (AIG) number: 0108896001; AHFS:
APPROVED
2023-07-21
BUPIVACAINE INJECTION BP PAGE 1 OF 32 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION BUPIVACAINE INJECTION BP Bupivacaine Injection Solution, 2.5 mg / mL and 5 mg / mL bupivacaine hydrochloride, Parenteral – Epidural Block / Infiltration BP Local Anesthetic EUGIA PHARMA INC. 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8 CANADA Date of Initial Authorization: JUL 21, 2023 Date of Revision: FEB 20, 2024 Submission Control Number: 283295 BUPIVACAINE INJECTION BP PAGE 2 OF 32 RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, GENERAL, HEPATIC/BILIARY/PANCREATIC 02/2024 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics ........................................................................................................................... 4 1.2 Geriatrics ........................................................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................... 5 4 DOSAGE AND ADMINISTRATION ....................................................................................... 5 4.1 Dosing Considerations ..................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ................................................................. 6 4.3 Reconstitution ................................ Read the complete document